merged_alzheimers-treatment-kisunla-donanemab.txt


<question_number>1</question_number>
<answer>safety risks outweigh potential slight benefit</answer>

<question_number>2</question_number>
<answer>might discourage participation in trials for better treatments</answer>

<question_number>3</question_number>
<answer>no correlation</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<question_number>5</question_number>
<answer>patients can stop treatment after amyloid clearance</answer>

<question_number>6</question_number>
<answer>might reduce willingness to participate in other trials</answer>

<question_number>7</question_number>
<answer>monthly infusions and discontinuation after amyloid clearance</answer>

<question_number>8</question_number>
<answer>amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>intermediate tau levels</answer>